Teva Pharmaceutical Industries Limited income statement & cash flow
In the fiscal year ended Dec 31, 2025, Teva Pharmaceutical Industries Limited reported net income of $1.41B on revenue of $17.26B. Operating cash flow was $1.65B.
Income statement and cash flow summary
| Fiscal year ended | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.90B | $21.85B | $18.27B | $16.89B | $16.66B | $15.88B | $14.93B | $15.85B | $16.54B | $17.26B |
| Gross profit | $11.65B | $10.62B | $8.30B | $7.54B | $7.73B | $7.59B | $6.97B | $7.64B | $8.06B | $8.94B |
| Operating income | $2.15B | −$17.48B | −$1.64B | −$443.00M | −$3.57B | $1.72B | −$2.20B | $433.00M | −$303.00M | $2.16B |
| Net income | $329.00M | −$16.27B | −$2.15B | −$999.00M | −$3.99B | $417.00M | −$2.45B | −$559.00M | −$1.64B | $1.41B |
| Diluted EPS | $0.07 | −$16.26 | −$2.35 | −$0.91 | −$3.64 | $0.38 | −$2.20 | −$0.50 | −$1.45 | $1.21 |
| Operating cash flow | $3.89B | $2.23B | $2.45B | $748.00M | $1.22B | $798.00M | $1.59B | $1.37B | $1.25B | $1.65B |
| Capital expenditures | $901.00M | $874.00M | $651.00M | $525.00M | $578.00M | $562.00M | $548.00M | — | — | — |
| Reported in | 10-K 2019 | 10-K 2020 | 10-K 2021 | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 | 10-K 2026 |
Margins
Each figure divided by revenue for the same fiscal year.
| Fiscal year ended | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| Dec 2025 | 51.8% | 12.5% | 8.2% |
| Dec 2024 | 48.7% | -1.8% | -9.9% |
| Dec 2023 | 48.2% | 2.7% | -3.5% |
| Dec 2022 | 46.7% | -14.7% | -16.4% |
| Dec 2021 | 47.8% | 10.8% | 2.6% |
Source: SEC EDGAR XBRL company facts for CIK 818686 (raw data). Most recent filing in this dataset: 10-Q filed Nov 3, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.